Researchers have discovered common biological mechanisms across various psychiatric disorders by examining postmortem brain samples from the dorsolateral prefrontal cortex. Instead of focusing on gene expression in a broad sense, they zeroed in on exons—the specific segments that shape protein production. Interestingly, they found gene activity differences emerged clearly only at this more detailed level, not at the overarching whole-gene level. The study highlighted shared disruptions in stress hormone regulation, dopamine signaling, and circadian rhythms among multiple disorders, like schizophrenia.
Key facts include:
- Exon-Level Insights: Differences between psychiatric patients and healthy individuals appeared specifically at the exon level rather than the whole-gene level.
- Shared Pathways: Disruptions related to circadian rhythm, cortisol release, and dopamine pathways were evident across disorders.
- Towards Precision Psychiatry: The findings advocate for classifying psychiatric disorders by their biological mechanisms rather than just their symptoms.
The work, conducted by experts at the Max Planck Institute of Psychiatry, Helmholtz Munich, and the University of Sydney, involved analyzing brain tissue samples that were primarily sourced from schizophrenia patients alongside healthy controls. The dorsolateral prefrontal cortex is a crucial area related to reasoning and emotions, often linked to psychiatric conditions.
What stands out in this study is the team’s integration of multiple layers of genetic data. As Karolina Worf, the lead author, notes, by examining exons rather than entire genes, they gained deeper insights into how genetic variations can elevate disease risk.
Exons serve as vital segments within genes that not only help construct proteins but also determine the specific protein versions produced through a process known as alternative splicing, which affects over 95% of human genes.
The focus on exon-level differences proved critical. While no noteworthy differences at the gene level were found between psychiatric patients and controls, significant disparities emerged at the exon level. Janine Knauer-Arloth, who leads the Project Group Medical Genomics at the Max Planck Institute, points out that the likelihood of developing a psychiatric disorder hinges not just on the genes themselves but also on how these genes express.
The research team merged various genetic data sets, looking at single nucleotide polymorphisms (SNPs), rare genetic variants, and polygenic risk scores that compile an individual’s disease risk based on genetic factors. This approach allowed them to pinpoint disruptions in pathways tied to circadian rhythms, cortisol release, and dopamine signaling across the three studied disorders.
The findings suggest a shared biological foundation among psychiatric disorders, which could lead to a future where classifications are based more on biological mechanisms rather than solely on observable symptoms—a significant pivot toward more precise diagnostics and treatment options.
This research emphasizes the potential for integrating genetic insights with clinical practice to better understand and address mental health conditions.
